Particularly in the context of adenocarcinoma, reliable evidence is available suggesting that cancer development and progression might be led by the addiction from aberrant pathways triggered by genetic abnormalities acting as oncogenic drivers (such as the activating mutation of EGFR or the translocation of ALK). This evidence concerns the gene ALK and adenocarcinoma.